Tauriga Sciences Inc. Subsidiary Honeywood LLC's Berkeley, California Based Headquarters and Production Facility Now Operational

Tauriga logo

BERKELEY, Calif., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Tauriga Sciences, Inc. (OTCQB:TAUG) ("Tauriga" or the "Company"), a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, is pleased to announce that its wholly owned subsidiary Honeywood LLC ("Honeywood") has successfully transitioned into its new Berkeley, California based headquarters and production facility. This new Honeywood headquarters complex includes: corporate offices for administrative activities, a substantially improved production facility, and laboratory space for research and development ("R & D") activities. Additionally Honeywood has moved its CO2 extraction machine into this new facility and is gearing up for another production run in the near future. In addition to its Doc Green's topical cannabis cream, which is already available in dispensaries in California, Honeywood has developed Vapura, a soon-to-be-launched medicinal cannabis vapor cartridge that attaches to an e-cigarette battery and produces an effective and flavorful cannabis vapor.

Since its inception, Honeywood has been responsible for overseeing the product development of Doc Green's Healing Collective, formulating and licensing its line of Doc Green's Therapeutic Healing Cream, a cannabis infused shea butter lotion, that delivers the healing power of cannabis through the skin without psychoactive side effects. Doc Green's itself is a California not for profit entity operating under California laws, regulations, and guidelines applicable to the State's medicinal cannabis industry. Doc Green's lotion was the first professionally packaged and widely distributed cannabis product on the California market, and has won much acclaim including a first ("1st") prize award at the 2013 High Times Cannabis Cup ("Cannabis Cup") for Best Non-Edible Medically Infused Product.

Honeywood is a key component in Tauriga's natural wellness business. Honeywood is currently focused on increasing its capacity to produce and develop products, and is actively pursuing expansion opportunities in California as well as in other states where medical marijuana is legal. By completing the merger with Tauriga, Honeywood is confident that the quality of the management team and the access to working capital will enable both the acceleration of organic growth and expansion to new markets, resulting in new and greater revenues.

About Tauriga Sciences, Inc.:

Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company's business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. On July 10, 2014, Tauriga acquired a California based topical cannabis cream company. Please visit the Company's corporate website at www.tauriga.com.


This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.


Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.

CONTACT: Tauriga Sciences, Inc.: Dr. Stella M. Sung Chairman and Chief Executive Officer Tauriga Sciences, Inc. www.tauriga.com San Diego: + 1-858-353-5749 Montreal: + 1-514-840-3697 Email: ssung@tauriga.com

Source:Tauriga Sciences Inc